Validation of calibrated RIP (respiratory inductive plethysmography) based biomarker for diagnosis of SDB (sleep-disordered breathing) and the identification of an accessible screening solution

Informacje na temat projektu

Respiratory Analyzer

Identyfikator umowy o grant: 683740

DOI

10.3030/683740

Projekt został zamknięty

Data podpisania przez KE 29 Maja 2015

Data rozpoczęcia 1 Czerwca 2015

Data zakończenia 31 Października 2015

Finansowanie w ramach

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Koszt całkowity

€ 71 429,00

Wkład UE

€ 50 000,00

Koordynowany przez

NOX MEDICAL EHF
Iceland

Periodic Reporting for period 1 - Respiratory Analyzer (Validation of calibrated RIP (respiratory inductive plethysmography) based biomarker for diagnosis of SDB (sleep-disordered breathing) and the identification of an accessible screening solution)

Okres sprawozdawczy: 2015-06-01 do 2015-10-31

Podsumowanie kontekstu i ogólnych celów projektu

Nox Medical will validate a biomarker for Sleep disordered breathing (SDB). The Biomarker consists of calibrated RIP belt measurements, giving information about the breathing quality and sleep quality. The deliverables for the phase 1 study is a list of clinical partners from 7 different countries, results of two pilot validation studies and a business plan.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

Two pilot studies were carried out on the clinical relevance of the Biomarker. The studies included a physiological validation of the Biomarker by comparing it to a gold standard invasive method of measuring respiratory effort, and a comparison of the Biomarker with clinical outcomes in teenagers. The results presented at the World Sleep conference in Istanbul showed that the Biomarker can be used as a surrogate measure of the underlying physiology and it correlates with clinical outcomes. (see image 1)
The marketing effort related to the feasibility study involved visiting conferences and exhibitions, and contacting customers worldwide during the study. The results generated in the Feasibility study inspire further clinical validation of the Biomarker.
The market research clearly identified a need in the market for the Biomarker and possible applications of the Biomarker extend far beyond sleep science. The market is waiting for a solution that can be applied to diagnose SDB both to be able to diagnose patients who suffer from SDB and are not diagnosed with current methods, and to diagnose the underlying cause of SDB in patients and target treatment to the cause. The Biomarker needs to be clinically validated to be accepted as a basis for diagnostics.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

The business idea will be pursued. Nox Medical aims to change the paradigm of sleep diagnostics, allowing physicians to diagnose patients suffering from conditions linked to SDB and to diagnose the underlying cause of SDB in their patients. This will allow un-treated patient groups to get treatment and physicians to target treatment to the underlying cause of the disease.

To fully exploit the market opportunity two main tasks need to be worked on:
1) Nox Medical has applied for Phase II in the SME Instrument to finance clinical validation of the Biomarker. This will allow Nox Medical to augment current sleep diagnostics and allow sleep specialists to enhance their diagnostics capabilities to diagnose patients who cannot be diagnosed with current methods.
2) A development of a novel sleep diagnostics device and service that allows other medical professionals than sleep specialists to use sleep diagnostics as a routine diagnostics tool.

The development of this solution will mark the start of a revolution in sleep diagnostics devices.

breathing-efficiency.jpg